Page 72 - Read Online
P. 72
Eng et al. J Cancer Metastasis Treat 2019;5:69 I http://dx.doi.org/10.20517/2394-4722.2019.021 Page 13 of 13
agents. Nat Rev Clin Oncol 2019;16:185-204.
94. Huggett B, Paisner K. The commercial tipping point. Nat Biotechnol 2017;35:708-9.
95. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug
Discov 2017;16:203-22.
96. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, et al. Safety and activity of microRNA-loaded minicells in patients with
recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 2017;18:1386-96.
97. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice
weekly in patients with advanced solid tumors. Invest New Drugs 2017;35:180-8.
98. Vo DD, Staedel C, Zehnacker L, Benhida R, Darfeuille F, et al. Targeting the Production of Oncogenic MicroRNAs with Multimodal
Synthetic Small Molecules. ACS Chem Biol 2014;9:711-21.
